60 results on '"Caviglia, GIAN PAOLO"'
Search Results
2. Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
3. A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis
4. Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease
5. A nutrigenetic precision approach for the management of non-alcoholic fatty liver disease
6. Patients with inflammatory bowel disease are at increased risk of atherothrombotic disease: A systematic review with meta-analysis
7. Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function
8. The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease
9. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease
10. Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants
11. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection
12. AISF position paper on liver disease and pregnancy
13. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis
14. Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers
15. Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner
16. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients
17. FRI-405 Heterogeneity in the diagnostic performances of HDV-RNA quantification assays used in clinical practice in Italy: results from a national quality control multicenter study
18. FRI-392-YI Chronic HDV coinfection (CHD) is characterized by a more elevated production of Middle and Large HBsAg than HBV monoinfection, that parallels HDV replicative and cytolytic activity
19. THU-517 Off-label use of nivolumab beyond first-line in advanced hepatocellular carcinoma: experience from two international centres
20. WED-293 Effectiveness of on different models of care based on Fibrosis-4 and/or liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease
21. WED-243-YI Irisin level as a potential biomarker for hepatic steatosis improvement after a 6-month lifestyle intervention in patients with metabolic dysfunction-associated steatotic liver disease
22. WED-233-YI The single nucleotide polymorphism rs780094 C>T in the glucokinase regulator gene (GCKR) is associated with hepatic steatosis improvement after lifestyle intervention in overweight/obese subjects with metabolic dysfunction-associated steatotic liver disease
23. FRI-314 Plasminogen activator inhibitor-1 (PAI-1) is associated with hepatic steatosis improvement after lifestyle intervention in overweight/obese subjects with metabolic-dysfunction associated steatotic liver disease
24. FRI-251-YI Hepatic steatosis contributes to cognitive impairment in patients with metabolic dysfunction-associated steatotic liver disease and/or type 2 diabetes-mellitus
25. FRI-243 Echocardiography-based markers of subclinical cardiac dysfunction in patients with MASLD and preserved ejection fraction: prospective data from the Turin cohort
26. FRI-230-YI Prevalence and predictors of steatotic liver disease and significant liver fibrosis in an integrated hepatological and nonhepatological healthcare pathway model: preliminary results from a prospective cohort of a tertiary center
27. THU-486-YI A multi-center comparison of Atezolizumab plus Bevacizumab and Lenvatinib as primary systemic therapy for unresectable hepatocellar carcinoma: focus on thrombotic and hemorragic adverse events
28. FRI-479-YI The role of OSM/OSMRβ axis in shaping the immunemicroenvironment favouring MASLD-related HCC immune evasion
29. SAT-031-YI Evolution of pre liver transplant cardiovascular risk factors and cardiac work-up: impact on post-transplant events
30. SAT-015-YI Screening for asymptomatic coronary artery disease in liver transplant recipients: is it time to replace stress echocardiography with coronary CT angiography in selected patients?
31. OS-094 Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBV-DNA in the setting of a limited or even absent HBV reservoir
32. Reply to: “The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis”
33. Outcome of chronic delta hepatitis in Italy: A long-term cohort study
34. Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?
35. Chapter 2 - Induced pluripotent stem cells from spermatogonial stem cells: potential applications
36. Hepatitis D virus in Uzbekistan
37. WED-133 - Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage
38. TOP-106 - The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir
39. SAT-494 - Echocardiography-based markers for subclinical cardiac dysfunction in patients with non-alcoholic fatty liver disease and significant fibrosis with preserved ejection fraction: preliminary data from a prospective monocentric Italian cohort
40. SAT-474 - AGILE 3+ and AGILE 4 scores for the diagnosis of advanced fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease
41. SAT-430 - Burden of non-alcoholic fatty liver disease and usefulness of non-invasive tests to identify advanced liver disease in patients with type 2 diabetes mellitus: interim analysis of an Italian prospective multicentre study
42. THU-470 - Impact of PNPLA3 rs738409 single nucleotide polymorphism and carbohydrate intake for the personalized management of patients with non-alcoholic fatty liver disease
43. THU-452 - Interferon gamma-induced protein 10 levels increase across the spectrum of liver disease and are associated with insuline resistant components in subjects with non-alcoholic fatty liver disease
44. THU-435 - Influence of chronotype and adherence to the mediterranean diet on the risk of liver fibrosis in patients with non-alcoholic fatty liver disease
45. THU-425 - De novo lipogenesis discriminates advanced hepatic fibrosis after an oral glucose load in non-obese subjects with non-alcoholic fatty liver disease
46. THU-415 - Glucose and lipid metabolism alterations after an oral lipid meal in patients with non-alcoholic fatty liver disease carrying the PNPLA3 rs738409 polymorphism
47. FRI-325 - Prognostic value of simple non-invasive tests for the risk stratification of HCC development in patients with cirrhosis due to non-alcoholic fatty liver disease
48. Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors
49. Contributors
50. SAT196 - Efficacy of transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.